Prostate cancer Monte Carlo dose model with 177Lutetium and 125Iodine treatments
Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): B. Juste, R. Miró, S. Morató, G. Verdú, S. Peris
Publication date: Available online 30 May 2020Source: European UrologyAuthor(s): Heidi Fettke, Edmond M. Kwan, Maria M. Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G. Horvath, Arun A. Azad
Authors: Lin M, Bu C, He Q, Gu J, Wang H, Feng N, Jiang SW Abstract TAZ (transcriptional coactivator with PDZ‑binding motif), which is also known as WW domain‑containing transcription regulator 1 (WWTR1), a downstream effector of the Hippo pathway, has been reported to regulate cancer cell proliferation, migration and apoptosis by acting as a transcriptional coactivator. However, the function of TAZ in prostate cancer cells has not been investigated. In the present study, TAZ expression in prostate cancer (PCa) and benign prostatic hyperplasia tissues, PCa cell lines, and normal prostate epithelial cells was de...
Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo.
(Institute of Cancer Research) Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows.
Authors: Moussa M, Papatsoris A, Abou Chakra M, Sryropoulou D, Dellis A Abstract INTRODUCTION: Metastatic castration-resistant prostate cancer (CRPC) is a potentially symptomatic disease with an eventual lethal outcome. Novel pharmaceutical agents are continuously studied with encouraging results in CRPC. AREAS COVERED: In this perspective, the authors present established and promising pharmacotherapeutic strategies for the management of CRPC; both with and without metastases. Apart from the different treatment strategies, the authors present the relevant sequence of treatment through disease progression. E...
This study aims to investigate prostate cancer in younger men (
Publication date: Available online 30 May 2020Source: Annals of Medicine and SurgeryAuthor(s): Francesco Ziglioli, Marco Baciarello, Giada Maspero, Valentina Bellini, Tommaso Bocchialini, Domenico Cavalieri, Elena Giovanna Bignami, Umberto Maestroni
Abstract Identification and clinical translation of routinely tested biomarkers require a complex and multistep workflow. Here, we described a confirmatory process estimating the utility of previously identified candidate tissue miRNAs for diagnosis of prostate cancer (PCa). RNA was isolated from formalin-fixed paraffin-embedded (FFPE) prostate tissue surgically resected from 44 patients with PCa and 24 patients with benign prostate hyperplasia (BPH). Of the 92 RNA samples obtained, 68 represented 42 malignant (PCa) areas and 26 represented nonmalignant (PCa 0%) areas of the prostate tissue sections. The levels of...
The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.
ConclusionsThe increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.